TOSS, ANGELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.110
AS - Asia 5.828
EU - Europa 5.027
SA - Sud America 1.080
AF - Africa 138
OC - Oceania 44
Continente sconosciuto - Info sul continente non disponibili 10
Totale 23.237
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.922
CN - Cina 1.752
SG - Singapore 1.692
IT - Italia 1.304
GB - Regno Unito 1.039
HK - Hong Kong 888
BR - Brasile 878
SE - Svezia 564
DE - Germania 516
VN - Vietnam 472
IE - Irlanda 334
RU - Federazione Russa 311
FI - Finlandia 177
ID - Indonesia 170
KR - Corea 168
FR - Francia 150
IN - India 148
TR - Turchia 106
UA - Ucraina 102
BG - Bulgaria 95
CA - Canada 87
JP - Giappone 82
AR - Argentina 81
NL - Olanda 77
MX - Messico 71
PL - Polonia 60
ES - Italia 53
IQ - Iraq 52
BD - Bangladesh 46
ZA - Sudafrica 46
LT - Lituania 40
TW - Taiwan 40
AT - Austria 39
AU - Australia 39
MY - Malesia 35
EC - Ecuador 34
EG - Egitto 34
IR - Iran 28
CO - Colombia 27
PK - Pakistan 26
BE - Belgio 21
MA - Marocco 18
VE - Venezuela 18
CZ - Repubblica Ceca 17
NO - Norvegia 15
UZ - Uzbekistan 15
CL - Cile 14
PH - Filippine 14
MD - Moldavia 13
GR - Grecia 12
SI - Slovenia 12
PY - Paraguay 11
RO - Romania 11
AZ - Azerbaigian 10
IL - Israele 10
AE - Emirati Arabi Uniti 9
KE - Kenya 9
DK - Danimarca 8
SA - Arabia Saudita 8
TH - Thailandia 8
AL - Albania 7
BO - Bolivia 7
CH - Svizzera 7
HU - Ungheria 7
KZ - Kazakistan 7
LV - Lettonia 6
EU - Europa 5
GE - Georgia 5
GH - Ghana 5
HR - Croazia 5
KG - Kirghizistan 5
MT - Malta 5
NZ - Nuova Zelanda 5
PA - Panama 5
PE - Perù 5
SY - Repubblica araba siriana 5
TN - Tunisia 5
DO - Repubblica Dominicana 4
HN - Honduras 4
RS - Serbia 4
XK - ???statistics.table.value.countryCode.XK??? 4
BY - Bielorussia 3
CY - Cipro 3
DZ - Algeria 3
IS - Islanda 3
JO - Giordania 3
MK - Macedonia 3
PS - Palestinian Territory 3
PT - Portogallo 3
SN - Senegal 3
UY - Uruguay 3
AM - Armenia 2
BB - Barbados 2
BZ - Belize 2
CD - Congo 2
CG - Congo 2
CR - Costa Rica 2
DM - Dominica 2
GT - Guatemala 2
GY - Guiana 2
Totale 23.198
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.320
Ashburn 1.253
Fairfield 1.185
Singapore 991
Hong Kong 871
Chandler 777
Hefei 685
Woodbridge 561
Seattle 496
Houston 434
Cambridge 403
Southend 402
Wilmington 350
Nyköping 349
London 342
Dublin 329
Beijing 262
Dallas 258
Los Angeles 220
Ann Arbor 215
Dearborn 211
New York 204
Modena 191
Ho Chi Minh City 171
Seoul 153
Jakarta 136
Chicago 131
Helsinki 113
San Diego 111
Jacksonville 103
Princeton 100
Bologna 97
Milan 96
Sofia 94
Moscow 90
Munich 90
Hanoi 88
São Paulo 86
Shanghai 75
Council Bluffs 68
Tokyo 63
Bremen 59
Buffalo 55
The Dalles 53
Eugene 52
Izmir 52
Redwood City 52
Salt Lake City 48
Warsaw 48
Frankfurt am Main 46
Fremont 44
Rome 44
Dong Ket 40
Kent 40
Lauterbourg 40
Reggio Emilia 40
Nuremberg 35
Guangzhou 32
Redondo Beach 32
Phoenix 31
Portsmouth 30
Rio de Janeiro 30
Baghdad 29
Columbus 29
Falls Church 28
Johannesburg 28
San Giuliano Milanese 28
Brooklyn 27
Düsseldorf 27
Mexico City 27
Belo Horizonte 26
Turku 26
Haiphong 25
Lappeenranta 25
Parma 25
Atlanta 24
Montreal 24
Poplar 23
Stockholm 23
Toronto 23
Denver 22
Lawrence 22
Vienna 22
Asyut 21
Sydney 21
Brasília 20
Orem 20
Boardman 19
Norwalk 19
Brussels 18
Campinas 18
Elk Grove Village 18
Chennai 17
Florence 17
Paris 17
Sterling 16
Tampa 15
Turin 15
Amsterdam 14
Banqiao 14
Totale 15.909
Salva come PNG Salva come JPEG
Nome #
Cancer Treatment Induced Bone Loss (CTIBL) in breast cancer women: a multidisciplinary approach at the Modena Cancer Center screening over 600 patients. 515
Impressive response to dose-dense chemotherapy in a patient with NUT midline carcinoma 427
A rapid genetic counselling and testing in newly diagnosed breast cancer is associated with high rate of risk-reducing mastectomy in BRCA1/2-positive italian women 420
Endocrine sensitive metastatic breast cancer and bone only disease: are the new treatments always better? 378
Differential molecular pathways expression in HER2 positive early breast cancer according to hormone receptor status. 315
ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. 313
Abstracts from the 55th European Society of Human Genetics (ESHG) Conference: Hybrid Posters 309
Genomic alterations at the basis of treatment resistance in metastatic breast cancer: Clinical applications 307
Molecular mechanisms of PARP inhibitors In BRCA-related ovarian cancer 300
Ovarian cancer: can proteomics give new insights for therapy and diagnosis? 294
Interstitial Lung Disease in Abemaciclib-treated Patients during SARS-CoV-2 Pandemic: A Case Series. 294
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies 281
Predictive role of haemoglobin on disease response to neoadjuvant chemotherapy in breast cancer. 277
Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients. 277
Hereditary Ovarian Cancer: Not Only BRCA 1 and 2 Genes 258
Combined Hormonal Contraceptive Use and Risk of Breast Cancer in a Population of Women With a Family History 255
Primary and secondary prevention to effectively reduce the risk of bisphosphonate-related osteonecrosis of the jaw in patients with bone metastases . 255
Tumor size, node status, grading, HER2 and estrogen receptor status still retain a strong value in patients with operable breast cancer diagnosed in recent years. 250
The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life 249
Brca detection rate in an italian cohort of luminal early-onset and triple-negative breast cancer patients without family history: When biology overcomes genealogy 248
Reproductive risk factors in women with family history of breast cancer attending an Italian Family Cancer Clinic 242
First-Line Treatment for Endocrine-Sensitive Bone-Only Metastatic Breast Cancer: Systematic Review and Meta-analysis 239
NUT midline carcinoma of the head and neck: current perspectives 238
Evaluation of Transvaginal Ultrasound plus CA-125 Measurement and Prophylactic Salpingo-Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study 235
Molecular Biomarkers for Prediction of Targeted Therapy Response in Metastatic Breast Cancer: Trick or Treat? 234
Two-month stop in mammographic screening significantly impacts on breast cancer stage at diagnosis and upfront treatment in the COVID era 234
Lifestyle intervention on body weight and physical activity in patients with breast cancer can reduce the risk of death in obese women: The EMILI study 233
Breast ultrasonography (BU) in the screening protocol for women at hereditary-familial risk of breast cancer: has the time come to rethink the role of BU according to different risk categories? 225
Clinical-Pathological Characteristics of HER2+ Breast Cancers patients among BRCA1/2+ carriers tested in Modena Cancer Center. 224
Combined hormonal contraceptives in BRCA gene mutation carriers: why not? 222
Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy 218
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 216
Endocrine-based targeted combination versus endocrine therapy alone as first-line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trials. 216
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING MULTI-GENE PANEL 213
Clinical and Pathological Features of Breast Cancer in Systemic Sclerosis: Results from the Sclero-Breast Study 212
CLINICAL AND PATHOLOGICAL FEATURES OF BREAST CANCER IN PATIENTS WITH SYSTEMIC SCLEROSIS: PRELIMINARY DATA FROM THE SCLERO-BREAST STUDY 210
The impact of reproductive life on breast cancer risk in women with family history or BRCA mutation 208
Male mammary myofibroblastoma: Two case reports and brief review of literature 208
Clinicopathologic Profile of Breast Cancer in Germline ATM and CHEK2 Mutation Carriers 208
Thromboembolism (TE) and adjuvant endocrine therapy (AET) in hormone receptor positive (HR+) early breast cancer (EBC): Did the evolution of treatment change the incidence of the adverse event? A metanalysis 208
Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the modena familial breast and ovarian cancer center (Italy) 205
Increasing BMI is associated with both endometrioid and serous histotypes among endometrial rather than ovarian cancers: a case-to-case study 205
Chemoprevention strategies for high risk women 204
STRATEGIES TO PREDICT TREATMENT RESPONSE AND SELECT THERAPIES IN METASTATIC BREAST CANCER PATIENTS USING A NEXT GENERATION SEQUENCING (NGS) MULTI-GENE PANEL 202
Combined endocrine approaches vs endocrine therapy alone as first line treatment in elderly patients with hormone receptor-positive, HER2 negative, advanced breast cancer: To prescribe for the patient or the physician? A meta-analysis of phase II and III randomized clinical trials 202
First-line treatment for endocrine sensitive bone-only metastatic breast cancer: Is more always better? 201
Prediction of breast and prostate cancer risks in male BRCA1 and BRCA2 mutation carriers using polygenic risk scores 201
Hereditary ovarian cancers: State of the art 196
Fertility and pregnancy issues in BRCA-mutated breast cancer patients 195
Breast ultrasound in high-risk women 195
Relative and disease-free survival for breast cancer in relation to subtype: a population-based study 193
Twenty-years experience with de novo metastatic breast cancer 193
Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification 191
The role of exosomes in breast cancer diagnosis 190
Molecular characterization and targeted therapeutic approaches in breast cancer 188
Endocrine therapy alone versus targeted combination strategy as first line treatment in elderly patients with hormone receptor-positive advanced breast cancer: Meta-analysis of phase II and III randomized clinical trial 188
BRCA mutations among triple negative breast cancer without family history of breast and ovarian cancer: The Modena family cancer clinic experience 184
Association of genomic domains in BRCA1 and BRCA2 with prostate cancer risk and aggressiveness 183
Male Bilateral Risk-Reducing Mastectomy: Report of a Case 183
Postmenopausal hormone therapy in BRCA gene mutation carriers: to whom and which? 181
Characterization of new ATM deletion associated with hereditary breast cancer 179
Circulating and Intracellular miRNAs as Prognostic and Predictive Factors in HER2-Positive Early Breast Cancer Treated with Neoadjuvant Chemotherapy: A Review of the Literature 179
Radiological screening programs for women at high risk of developing breast cancer 178
BRCA mutation carriers' perceptions on postmenopausal hormone therapy: An Italian study 176
Carboplatin-paclitaxel in triple-negative metastatic breast cancer during pregnancy with neoplastic thrombosis 169
The generally low sensitivity of CA125 for FIGO stage I ovarian cancer diagnosis increases for endometrioid histotype 168
Quality of life of therapies for hormone receptor positive advanced/metastatic breast cancer: Regulatory aspects and clinical impact in Europe 168
PARP inhibitors for the treatment of ovarian cancer 166
Automated capture-based NGS workflow: one thousand patients experience in a clinical routine framework 166
BRCA mutation carriers’ perception about benefits and risks associated with combined hormonal contraceptives use 164
Real-World Data and Clinical Implications of Next-Generation Sequencing (NGS)-Based Analysis in Metastatic Breast Cancer Patients 162
Occult breast cancer: the uncommon presentation of a common disease 156
Satisfaction with prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers is very high and little dependent on the participants' characteristics at surgery: a prospective study 156
EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project 152
Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less 150
The reduction of CA 125 serum levels in BRCA 1/2 mutation carriers after risk-reducing salpingo-oophorectomy is only partially associated with surgery: A prospective cohort, other biomarker controlled, study 150
COVID-related disruption in mammographic screening: a year later. 148
Molecular Pathways of Breast Cancer in Systemic Sclerosis: Exploratory Immunohistochemical Analysis from the Sclero-Breast Study 147
Personalized Systemic Therapies in Hereditary Cancer Syndromes 143
Role of Intrinsic Subtype Analysis with PAM50 in Hormone Receptors Positive HER2 Negative Metastatic Breast Cancer: A Systematic Review. 142
Primary fallopian tube carcinoma (PFTC) in a BRIP-1 mutation carrier: the first case report 138
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour 137
BRCA mutation rate and characteristics of prostate tumor in breast and ovarian cancer families: analysis of 6,591 Italian pedigrees 136
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women with Triple-Negative Breast Cancer: A Phase 3 Randomized Clinical Trial 135
Obesity in Postmenopausal Breast Cancer Patients: It Is Time to Improve Actions for a Healthier Lifestyle. The Results of a Comparison Between Two Italian Regions With Different “Presumed” Lifestyles 134
Constitutional Mosaicism: A Critical Issue in the Definition of BRCA-Inherited Cancer Risk 131
Management of PALB2-associated breast cancer: A literature review and case report 129
LOW-FREQUENCY ALLELE VARIANTS IN NGS MULTI-GENE PANELS FOR HEREDITARY CANCER TESTING: ARTIFACTS, CHIP OR MOSAICS? MANAGING THE RESULTS IN THE LABORATORY ROUTINE 127
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting 127
Cancer Predisposition Genes in Adolescents and Young Adults (AYAs): a Review Paper from the Italian AYA Working Group 126
The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance 124
Chemoprevention strategies in hereditary breast and ovarian cancer syndromes 122
Breast cancer screening of mutation carriers in the era of COVID-19 pandemic 122
Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: Young oncologists' perspective 121
Extracellular vesicles-derived miR-21 as a biomarker for early diagnosis and tumor activity in breast cancer subtypes 120
Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy? 119
DCE-MRI Radiomic analysis in triple negative ductal invasive breast cancer. Comparison between BRCA and not BRCA mutated patients: Preliminary results 119
Automation of a capture-based NGS workflow: one thousand patients experience in a diagnostic clinical routine framework 117
Clinical behavior and outcomes of breast cancer in young women with germline BRCA pathogenic variants 116
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores 116
Totale 20.280
Salva come PNG Salva come JPEG
Categoria #
all - tutte 100.560
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 100.560
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.391 0 0 0 0 0 167 111 239 197 234 225 218
2021/20221.999 141 173 144 82 72 147 94 109 265 173 355 244
2022/20232.486 279 310 172 201 231 275 51 184 541 40 101 101
2023/20241.828 93 96 99 186 277 148 244 237 68 74 115 191
2024/20256.202 145 59 124 324 1.039 805 599 383 737 407 668 912
2025/20265.699 931 501 1.161 1.442 1.551 113 0 0 0 0 0 0
Totale 23.494